차세대 시퀀싱 서비스 시장 규모, 점유율 및 동향 분석 보고서 : 서비스 유형별, 워크플로우별, 최종 용도별, 지역별, 부문별 동향(2024-2030년)

Next-generation Sequencing Services Market Growth & Trends:

The global next-generation sequencing services market size is expected to reach USD 24.48 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 22.68% from 2024 to 2030. The development of next-generation sequencing (NGS) technologies has revolutionized gene sequencing in terms of reproducibility and cost savings. This has resulted in the introduction of several advancements in NGS technology to promote its usage in clinical labs and hospitals. Most current innovations in this field revolve around simplifying the usage of seq-technology and making it more sophisticated. These factors have driven the uptake of NGS services across various end-users.

Next-generation sequencing has progressed from research to clinical use in the last five years. Around 14 nations have launched large-scale genome sequencing programs, with nearly 60 million people expected to have their genome analyzed by 2025. Conventional disease testing service providers have broadened their portfolio with a rising trend of seq-based genetic tests. For instance, ARUP Laboratories announced the release of new coronavirus tests in March 2022, and IDbyDNA, Inc. partnered with another firm to introduce new coronavirus tests, an NGS test for respiratory illnesses, to aid physicians in evaluating patients with pneumonia and some other respiratory problems.

With the rising trend of high throughput sequencing within the pharma and biotech industry, there is a need for more developments to improve the speed and convenience of high throughput seq-platforms and simplify workflows. As a result, companies are focusing on the development of solutions to simplify the amplification and purification of samples and starting input. In March 2022, Illumina, Inc. announced the release of TruSigh Oncology (TSO) Comprehensive (EU), a comprehensive diagnostic that evaluates several tumor genes and indicators to identify a patient's cancer's individual molecular profile. The in vitro diagnostic (IVD) kit would assist in influencing genomic decisions for patients with cancer across Europe, with its global debut taking place first in Europe.

Next-generation Sequencing Services Market Report Highlights:

• By service type, human genome sequencing held the largest revenue share in 2023 owing to greater penetration of whole genome and whole exome sequencing
• Gene regulation services, particularly small RNA sequencing and ChIP-seq, are anticipated to grow at a lucrative pace during the forecast period. Rising investment in RNA sequencing is fueling the growth of gene regulation services
• The larger revenue share of sequencing services as compared to other workflow steps can be attributed to an increase in the installation of sequencing platforms. High maintenance and recovery costs of this step have also resulted in greater revenue generation
• By end-use, the universities and other research entities segment held the largest revenue share in 2023 owing to the growing application of NGS technology for cancer prognosis as well as diagnosis and major projects taken up by academicians and universities
• North America dominated the market in 2023 owing to higher penetration of the technology in this region and the availability of funds to employ the technique and derive research findings for disease targeting
• Companies such as GENEWIZ and Novogene Corporation are engaged in offering NGS services based on platforms from major NGS developers. Companies such as Illumina and BGI, on the other hand, are involved in developing sequencing instruments and offering services to research entities
• In November 2021, Novogene stated during the 44th Annual Gathering of Molecular Biological Society of Japan (MSBJ) in Japan that they will be launching single-cell sequencing services specifically for their Japanese customers
• GENEWIZ scientists are assisting in identifying the NGS solution for the projects. The NeXT Dx Test was launched by Personalis, Inc. to assist oncologists in identifying new therapy and clinical trial choices for cancer patients

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information analysis
  • 1.2.2. Market formulation & data visualization
  • 1.2.3. Data validation & publishing
• 1.3. Information Procurement
  • 1.3.1. Primary Others
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Market Model
• 1.7. Objectives
  • 1.7.1. Objective 1
  • 1.7.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Decline in sequencing prices
  • 3.3.2. Growing awareness pertaining to women & reproductive health
  • 3.3.3. Strategies undertaken for implementation of clinical NGS
• 3.4. Market Restraint Analysis
  • 3.4.1. Challenges pertaining to implementation of large-scale NGS analysis workflows
  • 3.4.2. Analytical challenges in single cell sequencing
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Service Type Business Analysis

• 4.1. Global Next Generation Sequencing Services Market: Service Type Movement Analysis
• 4.2. Human Genome Sequencing Services
  • 4.2.1. Human Genome Sequencing Services Market, 2018 - 2030 (USD Million)
• 4.3. Single-Cell Sequencing Services
  • 4.3.1. Single-Cell Sequencing Services Market, 2018 - 2030 (USD Million)
• 4.4. Microbial Genome-based Sequencing Services
  • 4.4.1. Microbial Genome-based Sequencing Services Market, 2018 - 2030 (USD Million)
• 4.5. Gene Regulation Services
  • 4.5.1. Gene Regulation Services Market, 2018 - 2030 (USD Million)
  • 4.5.2. Small RNA Sequencing Services
    • 4.5.2.1. Small RNA Sequencing Services Market, 2018 - 2030 (USD Million)
  • 4.5.3. Chip Sequencing Services
    • 4.5.3.1. Chip Sequencing Services Market, 2018 - 2030 (USD Million)
  • 4.5.4. Other Gene Regulation-based Service
    • 4.5.4.1. Other Gene Regulation-based Service Market, 2018 - 2030 (USD Million)
• 4.6. Animal & Plant Sequencing Services
  • 4.6.1. Animal & Plant Sequencing Services Market, 2018 - 2030 (USD Million)
• 4.7. Other Sequencing Services
  • 4.7.1. Other Sequencing Services Market, 2018 - 2030 (USD Million)

Chapter 5. Workflow Business Analysis

• 5.1. Global Next Generation Sequencing Services market: Workflow Movement Analysis
• 5.2. Pre Sequencing Service
  • 5.2.1. Pre Sequencing Service Market, 2018 - 2030 (USD Million)
• 5.3. Sequencing Service
  • 5.3.1. Sequencing Service Market, 2018 - 2030 (USD Million)
• 5.4. Data Analysis Service
  • 5.4.1. Data Analysis Service Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

• 6.1. Global Next Generation Sequencing Services Market: End-use Movement Analysis
• 6.2. Universities & Other Research Entities
  • 6.2.1. Universities & Other Research Entities Market, 2018 - 2030 (USD Million)
• 6.3. Hospitals & Clinics
  • 6.3.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
• 6.4. Pharma & Biotech Entities
  • 6.4.1. Pharma & Biotech Entities Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Global Next generation sequencing services market Share By Region, 2022 & 2030
• 7.2. North America
  • 7.2.1. North America Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Target Disease Prevalence
    • 7.2.2.5. U.S. Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Target Disease Prevalence
    • 7.2.3.5. Canada Next generation sequencing services market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Target Disease Prevalence
    • 7.3.2.5. Germany Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Target Disease Prevalence
    • 7.3.3.5. UK Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Target Disease Prevalence
    • 7.3.4.5. France Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Target Disease Prevalence
    • 7.3.5.5. Italy Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Target Disease Prevalence
    • 7.3.6.5. Spain Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Target Disease Prevalence
    • 7.3.7.5. Denmark Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Target Disease Prevalence
    • 7.3.8.5. Sweden Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Target Disease Prevalence
    • 7.3.9.5. Norway Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.3.10. Switzerland
    • 7.3.10.1. Key Country Dynamics
    • 7.3.10.2. Competitive Scenario
    • 7.3.10.3. Regulatory Framework
    • 7.3.10.4. Target Disease Prevalence
    • 7.3.10.5. Switzerland Next generation sequencing services market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Target Disease Prevalence
    • 7.4.2.5. Japan Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Target Disease Prevalence
    • 7.4.3.5. China Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Target Disease Prevalence
    • 7.4.4.5. India Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Target Disease Prevalence
    • 7.4.5.5. South Korea Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Target Disease Prevalence
    • 7.4.6.5. Australia Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Target Disease Prevalence
    • 7.4.7.5. Thailand Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.4.8. Singapore
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Target Disease Prevalence
    • 7.4.8.5. Singapore Next generation sequencing services market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Target Disease Prevalence
    • 7.5.2.5. Brazil Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Target Disease Prevalence
    • 7.5.3.5. Mexico Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.5.4. Argentina
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Target Disease Prevalence
    • 7.5.4.5. Argentina Next generation sequencing services market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Target Disease Prevalence
    • 7.6.2.5. South Africa Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Target Disease Prevalence
    • 7.6.3.5. Saudi Arabia Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Target Disease Prevalence
    • 7.6.4.5. UAE Next generation sequencing services market, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Target Disease Prevalence
    • 7.6.5.5. Kuwait Next generation sequencing services market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market/Position Share Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. Quest Diagnostics Incorporated
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. ARUP Laboratories
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Applied Biological Materials, Inc. (abm)
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Novogene Co, Ltd.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Azenta Life Sciences (GENEWIZ)
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. NanoString
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Illumina, Inc.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. PacBio
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Veritas
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. BGI (Beijing Genomics Institute)
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Gene by Gene Ltd.
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Strategic Initiatives
  • 8.4.12. Lucigen Corporation
    • 8.4.12.1. Overview
    • 8.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Strategic Initiatives